Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Endothelial p130cas confers resistance to anti-angiogenesis therapy

Cell Reports(2022)10.1016/j.celrep.2022.110301Source: DataRank Database

Endothelial p130cas confers resistance to anti-angiogenesis therapy is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)OA: goldTopics (31)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Anca Chelariu-Raicu ORCID,Sujanitha Umamaheswaran ORCID,Alpa M. Nick ORCID,Elaine Stur ORCID,Pahul Hanjra ORCID

Live enrichment

PubMed:35081345 PMC:PMC8860355

Deutsche Forschungsgemeinschaft

Grant: CH 1733/1-2

US Department of Defense

Grant: W81XWH-20-1-0335

National Institutes of Health

Grant: P50CA098258

National Institutes of Health

Grant: P30CA016672

National Institutes of Health

Grant: P50CA217685

National Institutes of Health

Grant: R35CA209904

NCI NIH HHS

Grant: R01 CA247220

NCI NIH HHS

Grant: T32 CA101642

National Comprehensive Cancer Network

Ovarian Cancer Research Alliance

American Cancer Society

Marsha Rivkin Center for Ovarian Cancer Research

goldLicense: cc-by-nc-nd

publisherhttp://www.cell.com/article/S2211124722000134/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124722000134?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124722000134?httpAccept=text/plain

repositoryhttps://doaj.org/article/d56e8ff2f87f4a398192d9812e8a3e98

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8860355

Fields of Study

Angiogenesis InhibitorsAnimalsBevacizumabCrk-Associated Substrate ProteinDrug Resistance, NeoplasmEndothelial CellsFemaleHumansMiceOvarian NeoplasmsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2

MeSH Terms

Endothelial CellsAnimalsHumansMiceOvarian NeoplasmsVascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsVascular Endothelial Growth Factor ADrug Resistance, NeoplasmFemaleCrk-Associated Substrate ProteinBevacizumab

Keywords

AngiogenesisAutophagyP130casAnti-angiogenic TherapyVegfr2Adaptive ResistanceTnks1bp1